New combination chemotherapy programme for bladder cancer.
Forty patients with either metastatic, post-radiotherapy recurrent, or poor prognosis locally advanced transitional cell carcinoma of the bladder were treated in a new combination chemotherapy programme with methotrexate, vinblastine, mitozantrone and JM8 (carboplatin); 33 patients were assessable for response. There were 9 complete responses (27%), 12 partial responses (36%) and 7 disease stabilizations (21%); 5 patients (15%) had progressive disease. The median duration of complete response has not been reached and is in excess of 9 months (range 4- greater than 18 months). This regimen was without significant toxicity and this is in contrast with M-VAC, which is thought to be currently the most effective treatment for urothelial cancer.
Waxman
J
J
Department of Clinical Oncology, Royal Postgraduate Medical School, Hammersmith Hospital, London.
Abel
P
P
James
N
N
Farah
N
N
O'Donoghue
E P
EP
Mee
D
D
Colbeck
R
R
Sikora
K
K
Williams
G
G
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D016190:Carboplatin; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*; D014747:Vinblastine / Q000008:administration & dosage
D009944:Organoplatinum Compounds; D014747:Vinblastine; D016190:Carboplatin; D008942:Mitoxantrone; D008727:Methotrexate